Tuesday , September 26 2023

USFDA WARNING LETTER

USFDA WARNING LETTER

USFDA 483 Warning Letter Dated MARCH 30, 2022

USFDA 483 Warning Letter Dated MARCH 30, 2022 This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, …

Read More »

All Post URL of Drugs formulations

Drugsformulations -

All Post URL of Drugs formulations Tablets MFR of Albendazole Tablets – (drugsformulations.com) MFR of Alfacalcidol & Calcium Carbonate Tablets (drugsformulations.com) MFR of Sildenafil Citrate Tablets (drugsformulations.com) MFR of Paracetamol & Dicyclomine HCl Tablets – (drugsformulations.com) MFR of Dextromethorphan, Bromhexine, Chlorpheniramine Maleate & Guaifenesin  Tablets (drugsformulations.com) Dextromethorphan (drugsformulations.com) Spiramycin Tablet (drugsformulations.com) MFR of Propranolol Hydrochloride …

Read More »

Pharma USFDA Warning Letter for Lohxa LLC

A 15 -

Lohxa LLC MARCS-CMS 581785 — September 10, 2019 For Warning Letter Click Here –   Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the letter recipient that may have changed the regulatory status of issues discussed in the letter. For more USFDA warning Letter …

Read More »

Pharma USFDA Warning Letter for Derma Pharm A/S MARCS-CMS

A 15 -

Teligent Pharma, Inc. MARCS-CMS 587592 — November 26, 2019 For Warning Letter Click Here –   Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the letter recipient that may have changed the regulatory status of issues discussed in the letter. For more USFDA warning …

Read More »

Pharma USFDA Warning Letter for OHM Pharma, Inc

A 15 -

OHM Pharma, Inc. MARCS-CMS 586428 — November 19, 2019 For Warning Letter Click Here –   Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the letter recipient that may have changed the regulatory status of issues discussed in the letter. For more USFDA warning …

Read More »

Pharma USFDA Warning Letter for Alkermes, Inc.

A 15 -

Alkermes, Inc. MARCS-CMS 597260 — December 02, 2019 For Warning Letter Click Here –   Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the letter recipient that may have changed the regulatory status of issues discussed in the letter. For more USFDA warning Letter …

Read More »

Pharma USFDA Warning Letter for Pharmalab Enterprises, Inc.

A 15 -

Pharmalab Enterprises, Inc. MARCS-CMS 588432 — December 10, 2019 For Warning Letter Click Here –   Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the letter recipient that may have changed the regulatory status of issues discussed in the letter. For more USFDA warning …

Read More »

Pharma USFDA Warning Letter for Wild Child WA Pty Ltd.

A 15 -

Wild Child WA Pty Ltd. MARCS-CMS 589463 — December 06, 2019 For Warning Letter Click Here –   Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the letter recipient that may have changed the regulatory status of issues discussed in the letter. For more …

Read More »

Pharma USFDA Warning Letter for Unipharma, LLC

A 15 -

Unipharma, LLC MARCS-CMS 585388 — November 06, 2019 For Warning Letter Click Here –   Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the letter recipient that may have changed the regulatory status of issues discussed in the letter. For more USFDA warning Letter …

Read More »

Pharma USFDA Warning Letter for LNK International, Inc.

A 15 -

LNK International, Inc. MARCS-CMS 582253 — September 26, 2019 For Warning Letter Click Here –   Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the letter recipient that may have changed the regulatory status of issues discussed in the letter. For more USFDA warning …

Read More »
error: Content is protected !!